Carbapenem Resistance-Determining Genes Among Multi-Drug Resistance Gram Negative Bacterial Cliinical Isolates From Bugando Medical Centre Tanzania
Material type:
Item type | Current library | Collection | Call number | Status | Barcode | |
---|---|---|---|---|---|---|
POSTGRADUATE DISSERTATIONS | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | NFIC | CREC/162023 (Browse shelf(Opens below)) | 1 | CREC/162023 |
Abstract:
Carberpenem resistance has been reported mostly in health care-associated infections (HAIs and it confers resistance to all beta lactam agents. In this study we aimed to determine the prevalence of carbapenem resistance determine genes (VIM, IMP_C, IMP_B, IMP-A, KPC, OXA_48 and NDM among multi drug resistance gram negative bacteria using molecular techniques.
This cross sectional study was conducted in MBN clinical laboratories Kampala Uganda between 1st of March to 16th of May 2013. A total of 236 multi drug resistance gram negative bacterials frozen from 2007 to 2012 in Microbiology laboratory of Catholic University of health and allied sciences Bugando were studied. The organisms were sub cultured on Muller Hinton agar, and DNA was extracted by boiling method. Uniplex PCR was performed using primers set obtained from MWG Ebensburg German.
Of 227 multidrug resistance gram negative bacteria isolates grow on subculture 96 (42%) were found to carry one or more of the carbaopenem resistance determine genes (CRDG). Of the genes studies VIM was the most frequent followed by IMP_C, detected in 34 (15%) and in 28 isolates (12%) of 227 multidrug resistance gram negative bacterial isolates studied, respectively. New Delhi metalo beta lactamase was the least found in 9 isolates (4%) of 227 multidrug resistance gram negative bacterial isolates. These genes were mostly detected in K. pneumonia, 33% followed by P. aeruginosa and E. coli 27% of each. Most of the bacteria with carbapenem resistance determining genes (CRDG) were from blood culture specimen (53%) and less prevalent in aspirates (33%).
There are no comments on this title.